anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: TAP Block utilizing 15ml of 0.75% ropivacaine per side

0.75% Ropivacaine: The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
Eligibility criteria:
Inclusion Criteria:

ASA II-III patient
> 18 years of age who is pregnant
presenting for a cesarean delivery via Pfannenstiel incision who is eligible to receive a spinal anesthetic with 0.75% bupivacaine and fentanyl and whose is not eligible to receive intrathecal morphine due to a BMI >40 kg/m2.

Exclusion Criteria:

< 18 years of age
contraindication to placement of a spinal anesthetic
contraindication to use of non-steroidal anti-inflammatory drugs (NSAIDs)
patients receiving medical therapies considered to result in tolerance to opioids
patients with a history of established chronic pain, (e.g. chronic low back pain, fibromyalgia or headaches), defined as requiring regular medical follow-up with pain specialists, as well as recent use (within the year preceding pregnancy) of opioid analgesics as an outpatient
patients with a history of diabetes mellitus
patients undergoing a vertical midline skin incision
patients who are undergoing a cesarean delivery after a failed vaginal trial of labor
patients who had a prior epidural placed for labor analgesia during the same hospital encounter.
Intervention: TERIPARATIDE
Trial phase: Phase 2
ATC code: H05AA02
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.

There were no adverse events related to the use of teriparatide.
Eligibility criteria:
Inclusion criteria:

Patients post bilateral thyroid bed surgery (cancer, Graves disease, multinodular goiter)
Symptomatic hypocalcemia
Total calcium < 8 mg/dL persisting after 24 hours of therapy with calcitriol (minimum 0.25 mcg twice a day) and calcium supplementation (minimum 1.5 grams of elemental calcium per day)
Parathyroid hormone (PTH) level below low end of normal range

Exclusion criteria (all subjects):

Renal failure
Any prior parathyroid pathology
Pre-existing hypercalcemia
Metabolic bone diseases other than osteoporosis
Pagets disease

Exclusion criteria (active treatment subjects only):

Ongoing therapy with Forteo for osteoporosis
Active non-thyroidal malignancy or suspicion of residual thyroid malignancy
History of skeletal malignancies, primary or metastatic
Pregnancy
Active or recent urolithiasis
Digitalis therapy
Patients at increased baseline risk for osteosarcoma, i.e., family history of osteosarcoma or prior radiation therapy involving the skeleton
Pediatric populations
Unexplained elevations of alkaline phosphatase
Intervention: Ibuprofen
Trial phase: Phase 3
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 89
Group description: Ibuprofen : 3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
Eligibility criteria:
Inclusion Criteria:

Healthy Male or female volunteer
Age 18-65
Sea-level dwelling
Non pregnant
Have not been to high altitude in the past week
Can arrange for their own transportation to WMRS by friday evening the weekend of their study enrollment and are available the duration of the weekend of their study enrollment

Exclusion Criteria:

Age <18 or >65
Live at altitude > Sea Level +/- 1000'
Pregnant
Taking NSAIDs, Acetazolamide, or Corticosteroids
Allergic to NSAIDs or Aspirin, or have had adverse reaction to them in the past
Traveled or planning to travel to high altitude in the week prior to their enrollment.
Medical history of Brain Tumor, increased intercranial pressure, pseudotumor cerebri, ventricular shunts, loss of an eye, Asthma, HACE or HAPE.
Cannot arrange for their own transportation to WMRS or are unavailable for the duration of the weekend of their study enrollment
Intervention: Modafinil
Trial phase: Phase 3
ATC code: N06BA07 | N06BA13
SMILES: NC(=O)CS(=O)C(c1ccccc1)c1ccccc1
Sex: All
Age groups: Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: participants who received modafinil (200 mg per day)
Eligibility criteria:
Inclusion Criteria:

diagnosis of mild to moderate stage Probable Alzheimer's disease
on a stable dose of a cholinesterase inhibitor medication for at least 30 days
clinically elevated levels of apathy as measured by the Frontal Systems Behavior Scale

Exclusion Criteria:

diagnosis of Major Depression
focal brain lesion on neuroimaging
history of significant substance abuse
history of significant head trauma with loss if consciousness >10 minutes
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Local anaesthetic bolus and infusion

Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM
Eligibility criteria:
Inclusion Criteria:

All patients >18 years of age and non pregnant presenting for elective knee replacement

Exclusion Criteria:

Signs of cardiac failure (3rd heart sound, lung crepitations)
Type I and type II diabetes
Abnormal cardiac arrhythmias
Hypovolaemia
Presence of seizures,
Dementia,
Depression
Encephalopathy,
Terminal illness with a life expectancy < 3 months
Age < 18 years
Pregnant
Coagulopathy
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Local anaesthetic bolus and infusion

Ropivacaine: Bolus and infusion
Eligibility criteria:
Inclusion Criteria:

All patients >18 years of age and non pregnant presenting for elective knee replacement

Exclusion Criteria:

Signs of cardiac failure (3rd heart sound, lung crepitations)
Type I and type II diabetes
Abnormal cardiac arrhythmias
Hypovolaemia
Presence of seizures,
Dementia,
Depression
Encephalopathy,
Terminal illness with a life expectancy < 3 months
Age < 18 years
Pregnant
Coagulopathy
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 5
Group description: N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.

N-Acetylcysteine: 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
Eligibility criteria:
Inclusion Criteria:

Children aged 8-17 years.
Primary diagnosis of OCD.
Duration of OCD greater than 6 months.
Significant Current OCD symptoms: Current CY-BOCS score > or = 16.

Exclusion Criteria:

Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental disorder or mental retardation (IQ<70).
Recent change (less than 4 weeks) in medications that have potential effects on OCD severity (such as Selective Serotonin Reuptake Inhibitors, clomipramine, naltrexone, lithium, psychostimulants, anxiolytics, or antipsychotics). Medication change is defined to include either dose changes or medication discontinuation.
Recent change in behavioral treatment for OCD or comorbid conditions within the last 4 weeks or initiation of behavioral therapy for tics within the last 12 weeks.
Asthma requiring medication use within the last 3 months (case reports have linked intravenous NAC administration with asthma exacerbation)
Known hypersensitivity or previous anaphylactoid reaction to acetylcysteine or any components in its preparation.
Positive pregnancy test or drug screening test.
Previous use of N-acetylcysteine (dose greater than 600mg for more than 2 weeks).
Previous history or suspicion of cystinuria because of a possibility of forming kidney stones.
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 17
Group description: N-Acetylcysteine (NAC): 1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
Eligibility criteria:
Inclusion Criteria:

Children aged 8-17 years.
Primary diagnosis of Tourette syndrome or chronic tic disorder.
Duration of tics greater than 1 year.
Significant Current tic symptoms: Current YGTSS score greater than or equal to 22 with a TS diagnosis or greater than or equal to 14 with a chronic tic disorder.

Exclusion Criteria:

Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental disorder or mental retardation (IQ<70).
Recent change (less than 4 weeks) in medications that have potential effects on tic severity (such as neuroleptic medications, dopamine agonists, alpha-2 agonists (guanfacine, clonidine or prazosin), SSRIs, clomipramine, naltrexone, lithium, psychostimulants, or anxiolytics). Medication change is defined to include dose changes or medication discontinuation.
Recent change in behavioral treatment for Tourette syndrome or comorbid conditions (i.e. OCD) within the last 4 weeks or initiation of behavioral therapy for tics within the last 12 weeks.
Asthma requiring medication use within the last 3 months
Known hypersensitivity or previous anaphylactoid reaction to acetylcysteine or any components in its preparation
Positive pregnancy test or drug screening test.
Previous use of N-acetylcysteine (dose greater than 600mg for more than 2 weeks)
Intervention: SODIUM BICARBONATE
Trial phase: Phase 3
ATC code: B05CB04 | B05XA02
SMILES: O=C([O-])O.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 301
Group description: hydration with sodium bicarbonate

sodium bicarbonate: hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
Eligibility criteria:
Inclusion Criteria:

serum creatinine > 1.1 mg/dL
glomerular filtration rate (GFR) < 50 mL/min

Exclusion Criteria:

age < 18 years
use of radiographic contrast media during the last 21 days
history of dialysis
cardiac insufficiency class III-IV
emergency procedures
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 301
Group description: hydration with saline 1ml/Kg/h for 6 hours

saline: hydration with saline 1ml/Kg/h for 6 hours
Eligibility criteria:
Inclusion Criteria:

serum creatinine > 1.1 mg/dL
glomerular filtration rate (GFR) < 50 mL/min

Exclusion Criteria:

age < 18 years
use of radiographic contrast media during the last 21 days
history of dialysis
cardiac insufficiency class III-IV
emergency procedures
Intervention: Lopinavir
Trial phase: Phase 2 | Phase 3
ATC code: J05AR10
SMILES: Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 97
Group description: Participants receiving lopinavir/ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines, in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.
Eligibility criteria:
Inclusion Criteria:

Weight equal to or greater than 3 kg, but less than 25 kg, at the time of enrollment
Confirmed diagnosis of HIV-1 infection
Lopinavir/ritonavir (LPV/r)-treatment naïve and LPV/r-treatment eligible as defined by country-specific guidelines or the WHO pediatric treatment guidelines and confirmed by investigator
Willingness to take two nucleoside reverse transcriptase inhibitos (NRTIs), in accordance with appropriate national or international treatment guidelines
Demonstrated ability and willingness to swallow tablets for children larger than 10 kg. This can be assessed before inclusion (for example, a test trial with similar size solid tablet such as tic-tac).
Participants in the weight band between 10 and 16.9 kg that are unable to swallow tablets will receive liquid formulation
Parent or legal guardian able and willing to provide written informed consent

Exclusion Criteria:

Planned concurrent use of non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, or an entry inhibitor
Planned concurrent protease inhibitor (PI) use, other than LPV/r
Prior treatment with LPV/r. Prior treatment with other PIs is allowed.
Results of certain laboratory tests indicating adverse events of Grade 3 or greater
Results of a lipase test indicating adverse event of Grade 2 or greater or clinical evidence of pancreatitis within 30 days prior to study entry
Tuberculosis co-treatment with rifampicin-containing regimen
Treatment with any enzyme-inducing antiepileptic drugs, such as henobarbital, phenytoin or carbamazepine
Clinical condition requiring the use of a prohibited medication (see protocol for more details)
Clinically unstable child requiring acute treatment for a serious opportunistic infection
Chemotherapy for active malignancy
Any clinically significant diseases (other than HIV-1 infection) or clinically significant findings during the screening medical history or physical examination that, in the investigator's opinion, would compromise participation in this study
Treatment with experimental drugs for any indication within 30 days prior to study entry
Known history of cardiac conduction abnormality and/or underlying structural heart disease, including congenital long QT
Intervention: Milnacipran
Trial phase: Phase 4
ATC code: N06AX17 | N06AX28
SMILES: CCN(CC)C(=O)C1(c2ccccc2)CC1CN
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Milnacipran was given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Eligibility criteria:
Inclusion Criteria:

You may be eligible to take part in this study if the following are true:

You are between the age of 18 and 70 years
If you are female
If you are right handed
You have a diagnosis of fibromyalgia for at least 3 months, as defined by the American College of Rheumatology 1990 Criteria
You are willing to stop taking certain medicines that you may be taking on a regular basis. The researchers will discuss these medications with you in detail

Exclusion Criteria:

You may not be eligible take part in this study if any of the following are true for you:

You have problems with your heart or cardiovascular system
You have problems with your liver or kidneys
You have an autoimmune disease, or a whole-body infection like HIV or hepatitis
You have cancer
You are pregnant or breastfeeding
You abuse drugs or alcohol
You have suicidal thoughts or wishes
You have taken milnacipran or another study drug within the last 30 days
You have a medical problem not listed here that would make it unsafe for you to take part in the study
The research team feels that you will be unable to complete all phases of the study
Intervention: Ganetespib
Trial phase: Phase 2
SMILES: CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 13
Group description: Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort A participants had relapsed > 60 days following initial chemotherapy completion.
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed diagnosis of small cell lung cancer and confirmed progressive disease by radiographic study
</= 3 prior chemotherapy regimens
Subjects with brain metastases will be allowed if they have been treated with surgery and/or radiation therapy > 21 days prior, are asymptomatic, and are stable for at least 1 week off steroids
Must have measurable disease
>/= 18 years of age
Life expectancy of greater than 12 weeks
EGOG performance status 0 or 1
Lab values must be within limits outlined in the protocol
Not pregnant or breastfeeding
Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Chemotherapy or radiotherapy within 3 weeks or within 5 half-lives of previous therapy
History of severe allergic or hypersensitivity reactions to taxanes.
Subjects who have not recovered from adverse events or toxicities due to agents administered more than 4 weeks earlier to a grade 1 or less
Not receiving any other study agents
History of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery.
Baseline QTc > 470 msec or previous history of QT prolongation while taking other medications.
Ventricular ejection fraction of < 55%.
History or current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block.
ECG with clinically significant ventricular arrhythmias or ischemia
Major surgery within 4 weeks of starting treatment
Poor venous access necessitating use of indwelling catheter for IV therapy
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance
History of another malignancy unless disease-free for 3 years and deemed to be at low risk for recurrence
Intervention: Minocycline
Trial phase: Phase 2
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Minocycline 100mg (capsule) two times a day during the entire course of radiation therapy (7 weeks ± 5 days)
Eligibility criteria:
Inclusion Criteria:

Patients with a pathologically proven diagnosis of oropharyngeal cancer, nasopharyngeal cancer, or unknown primary cancer of head and neck in MDACC receiving radiation therapy with or without induction chemotherapy.
Patients > = 18 years old.
Patients with the above cancers, T0, TX, T1 to T3, N any, M0 receiving IMRT (to unilateral or bilateral neck) at least 64-72 Gy in 6-7 weeks as definitive treatment.
Patients must have normal renal function test and no prior renal disease: The screening cut off for serum creatinine < upper limit of normal.
Patients must have normal hepatic function test and no prior liver disease: The screening results for total bilirubin must be < 1.5 times the upper limit of normal. The screening results for the following must be < 2 times the upper limit of normal for patients to be eligible: Alkaline phosphatase (ALP) and Alanine aminotransferase (ALT). The screening results for Aspartate aminotransferase (AST) must be < 2 times the upper limit of normal if available.
Patients who speak English (due to the novel research and its complexity, we are only accruing English speaking patients to the protocol).
Patients must be willing to discontinue taking dong quai and/or St John's wort.
Patients must be willing and able to review, understand, and provide written consent.

Exclusion Criteria:

Patients receiving concurrent chemotherapy or concurrent biologic agent.
Patients who are taking medications or have conditions that potentially preclude use of any study medications or interventions as determined by the treating physician.
Patients who are enrolled in another symptom management trial or receiving active treatment under another clinical trial.
Bile duct obstruction or cholelithiasis.
History of clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction, including multiple allergies or drug reaction.
Pre-existing psychosis or bipolar disorder.
Hypersensitivity to any tetracyclines.
Patients on anticoagulants (ie warfarin/heparin).
Patients with INR > 1.5.
Patients taking any tetracycline within the last 15 days.
Patients that are pregnant.
Patients treated with upfront radical surgery at the primary site (other than diagnostic tonsillectomy or excision).
Intervention: Vernakalant hydrochloride
Trial phase: Phase 3
SMILES: COc1ccc(CCOC2CCCCC2N2CCC(O)C2)cc1OC.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 55
Group description: vernakalant hydrochloride

Up to two 10-min infusions of 3mg/kg +/- 2mg/kg vernakalant IV
Eligibility criteria:
Inclusion Criteria:

Abstinent or willing to use 2 acceptable methods of birth control
Patient has an atrial arrhythmia with dysrhythmic symptoms
Patient is receiving adequate anticoagulant therapy
Patient has stable blood pressure
Patient weighs between 45 and 136 kg (99 and 300 lbs)
Patient is adequately hydrated

Exclusion Criteria:

Patient is pregnant, breast-feeding, or expecting to become pregnant during the study
Patient routinely consumes more than 2 alcoholic drinks per day
Patient has known or suspected prolonged QT, familial long QT syndrome, previous Torsades de Pointes, Brugada syndrome
Patient has known bradycardia, advanced AV block, or sick-sinus syndrome, unless controlled by a pacemaker
Patient has severe aortic stenosis
Patient has atrial flutter
Patient has Class IV congestive heart failure (CHF)
Patient has had a myocardial infarction (MI) or acute coronary syndrome (ACS)
Patient has had cardiac surgery within 30 days
Patient has known atrial thrombus
Patient has reversible causes of Atrial Fibrillation
Patient has failed electrical cardioversion during current episode of Atrial Fibrillation
Patient has uncorrected electrolyte imbalance
Patient has clinical evidence of digoxin toxicity
Patient has received certain antiarrhythmic drugs or intravenous amiodarone within 7 days
Patient is known to be HIV positive
Patient has a history of cancer within the past 5 years, except for certain skin or cervical cancers